REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 124 participants.
Also called NCT07006493
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 124 participants
- Sponsor
- SuZhou Sinus Medical Technologies Co.,Ltd
- Registry
-
NCT07006493
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07006493. Randomized; double masking; primary purpose treatment. Start 2025-07-20 (actual); primary completion 2026-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy
- Acronym
- REFINE-HCM
- Condition
- Hypertrophic Cardiomyopathy, Obstructive
- Intervention (Device)
- Transcatheter Intramyocardial Septal Radiofrequency Ablation System
- Lead sponsor
- SuZhou Sinus Medical Technologies Co.,Ltd
Record details
- Record id
cardio:ct-nct07006493- Content hash
8f26e4b62a89e860cd4e15cf53d0d062749f6dd362169c8abe129844532c9ba3